Educational Symposium
Glucagon-Like Peptide-1 Receptor Agonists Are Becoming Important Players in Diabetic Kidney Disease
November 04, 2023 | 12:45 PM - 01:45 PM
Location: Grand Ballroom Salon I, Level 5, Philadelphia Marriott Downtown
Session Description
Glucagon-like peptide-1 receptor agonists (GLP1 RAs) have shown favorable profiles in type 2 diabetes as glucose-lowering medications. Furthermore, evidence is growing, based on multiple clinical trials with GLP1 RAs, to suggest favorable profiles in subjects with diabetic or other chronic kidney diseases and possible renoprotection.
This symposium provides an overview of recent, large clinical trials with GLP1 RAs in subjects with type 2 diabetes, focusing on kidney outcomes in particular. Furthermore, GLP1 RA use is discussed in the context of other glucose-lowering or renoprotective treatment.
Support is provided by an educational grant from Novo Nordisk.
Learning Objective(s)
- Describe recent, large clinical trials on GLP1 RAs in type 2 diabetes
- Summarize kidney outcomes in recent clinical trials
- Discuss GLP1 RAs in the context of other treatments for diabetic kidney disease
Learning Pathway(s)
- Diabetic Kidney Disease
- CKD Non-Dialysis
Moderator
Presentations
- Introduction
12:45 PM - 12:55 PM
- GLP1 RAs and Kidney Outcomes in Diabetes
12:55 PM - 01:15 PM
- GLP1 RAs as a Part of the Diabetic Kidney Disease Therapeutic Landscape
01:15 PM - 01:35 PM
- Audience Q&A
01:35 PM - 01:45 PM